Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.1.3 (
ATPase
)
65,361
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long-term prospective studies comparing the effects of conventional and intensive insulin therapy have linked
diabetic hyperglycemia
to the development of diabetic retinopathy, nephropathy, and neuropathy. The mechanisms through which glucose metabolism leads to the development of these secondary complications, however, are incompletely understood. In animal models of diabetic neuropathy, the loss of nerve function in myelinated nerve fibers has been related to a series of biochemical changes. Nerve glucose, which is in equilibrium with plasma glucose levels, rapidly increases during
diabetic hyperglycemia
because glucose entry is independent of insulin. This excess glucose is metabolized in large part by the polyol pathway. Increased flux through this pathway is accompanied by the depletion of myo-inositol, a loss of Na/K
ATPase
activity and the accumulation of sodium. Supportive evidence linking these biochemical changes to the loss of nerve function has come from studies in which aldose reductase inhibitors block polyol pathway activity, prevent the depletion of myo-inositol and the accumulation of sodium and preserve Na/K
ATPase
activity, as well as nerve function. The kidney and red blood cells (RBCs) are two additional sites of diabetic lesions that have been reported to develop biochemical changes similar to those in the nerve. We observed that polyol levels in the kidney cortex, medulla, and RBCs increased two- to ninefold in rats following 10 weeks of untreated diabetes. Polyol accumulation was accompanied by a 30% decrease in myo-inositol levels in the kidney cortex, but no change in RBCs or the kidney medulla. Na/K
ATPase
activity was decreased by 59% in RBCs but was unaffected in the kidney cortex or medulla. Aldose reductase inhibitor treatment that preserved myo-inositol levels, Na/K
ATPase
, and conduction velocity in the sciatic nerve also preserved Na/K
ATPase
activity in RBCs. Our results suggest that the pathophysiologic mechanisms underlying diabetic neuropathy are different from those of diabetic nephropathy. Our results also suggest that RBCs maybe a surrogate tissue for the assessment of diabetes-induced changes in nerve Na/K
ATPase
activity.
...
PMID:Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats. 961 71
The present study evaluates the efficacy of ethanolic extract of Boerhaavia diffusa L (BD) administered orally at a dose of 500mg/kg body weight for a period of 30 days to alloxanized diabetic rats and its efficacy compared with the standard hypoglycaemic drug metformin. Diabetic animals showed glycemic dysregulation, altered ionic balance, increased levels of serum markers of kidney function, and reduced Na+-K+
ATPase
activity and endogenous antioxidant status. Administration of BD not only maintained the ionic balance and renal Na+-K+
ATPase
activity but also significantly minimized
diabetic hyperglycaemia
. The renal antioxidant status (GPx, Catalase, SOD and GSH) remained in the near normal range and LPO level lower than the non-diabetic level. These effects are comparable to the changes brought about by metformin treatment and even better. Over all, the present study provides evidence for BD to be a potent renoprotective and antihyperglycaemic agent in diabetic animals.
...
PMID:Antihyperglycaemic and renoprotective effect of Boerhaavia diffusa L. in experimental diabetic rats. 2275 25